InMode (INMD) Jefferies Global Healthcare Conference summary

Technology and product innovation

• Focus on radiofrequency-based, minimally invasive treatments for aesthetics, with proprietary bipolar RF technology enabling skin tightening and collagen retraction at targeted temperatures.

• Second-generation BodyTite and FaceTite platforms launching this year, with significant upgrades and a replacement cycle expected to drive value in Q3 and Q4.

• Morpheus platform enhancements improve treatment for skin of color, addressing the fastest-growing segment in aesthetics.

• Introduction of Quantum, a new internal bipolar RF device for superficial skin tightening, pending FDA approval and already generating excitement through a soft launch.

• Strong R&D pipeline includes new applications in women's health, overactive bladder, HPV, erectile dysfunction, and snoring, with timelines of 3-5 years for medical indications.

Business model and financial profile

• High gross margins (83%-85%) due to efficient RF technology and strong IP, enabling significant investment in sales and marketing.

• Leasing is a key sales channel, with many five-year leases from 2016-2017 now expiring, creating opportunities for upgrades and new sales.

• Product refresh cycle expected to start slow but could eventually represent a significant portion of sales, with initial focus on new customers this year.

• Capital allocation prioritizes disciplined M&A, but recent lack of suitable targets has led to a buyback program for up to 10% of outstanding shares.

Market trends and operational challenges

• Macro headwinds include reduced demand for aesthetic procedures, tighter financing conditions, and high interest rates, especially in North America.

• Supply chain challenges delayed shipments of new products, with catch-up expected by end of Q3 or possibly Q4, impacting revenue recognition timing.

• Risk-sharing financing programs with leasing partners have been implemented to speed up approvals and expand access to B credit customers.

• International markets, particularly Europe, showed growth in Q1 despite headwinds, while North America remains more sensitive to macroeconomic factors.